LH
PVLA

Lebenthal Holdings’s Palvella Therapeutics PVLA Stock Holding History

Lebenthal Holdings’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$16K Buy
+125
New +$19.2K ﹤0.01% 350

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Lebenthal Holdings's PVLA Position: Q2 2016 in Review

Lebenthal Holdings opened a new position in Palvella Therapeutics (PVLA) in Q2 2016: 125 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #350 among its holdings.

26 funds tracked by Wall St. Rank hold PVLA as of Q2 2016.

  • Lebenthal Holdings held 125 shares of Palvella Therapeutics worth $16K as of Q2 2016.
  • Palvella Therapeutics was a new Lebenthal Holdings position in Q2 2016.
  • Palvella Therapeutics made up ﹤0.01% of Lebenthal Holdings's portfolio in Q2 2016, its #350 holding.
  • 26 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2016.

Based on Lebenthal Holdings's 13F filing for Q2 2016, filed 19 Aug 2016.